{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:34Z","timestamp":1778822074989,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82401574"],"award-info":[{"award-number":["82401574"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116674","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:31:48Z","timestamp":1776526308000},"page":"116674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effects of anti-CD20 therapy on circulating T cells in patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"180","author":[{"given":"Qiu-Xia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Zhe","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao-Feng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116674_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.intimp.2026.116674_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"7","key":"10.1016\/j.intimp.2026.116674_bb0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.intimp.2026.116674_bb0020","article-title":"Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders","volume":"119","author":"Valentina Damato","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.intimp.2026.116674_bb0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"15","key":"10.1016\/j.intimp.2026.116674_bb0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.intimp.2026.116674_bb0035","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory b cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116674_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102727","article-title":"Efficacy and safety of rituximab in treating patients with neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis","volume":"20","author":"Mirmosayyeb","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2026.116674_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.22081","article-title":"B-cell activation influences t-cell polarization and outcome of anti-CD20 b-cell depletion in central nervous system autoimmunity","volume":"68","author":"Weber","year":"2010","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116674_bb0050","article-title":"Differential effects of anti-CD20 therapy on CD4 and CD8 t cells and implication of CD20-expressing CD8 t cells in MS disease activity","volume":"120","author":"Koji Shinoda","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.intimp.2026.116674_bb0055","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200268","article-title":"Serum proteomics distinguish subtypes of NMO spectrum disorder and MOG antibody-associated disease and highlight effects of B-cell depletion","volume":"11","author":"Gawde","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.intimp.2026.116674_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105886","article-title":"Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset","volume":"91","author":"Konen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.intimp.2026.116674_bb0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/acn3.51965","article-title":"Repeated iv anti-CD20 treatment in multiple sclerosis: long-term effects on peripheral immune cell subsets","volume":"11","author":"Feige","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116674_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.intimp.2026.116674_bb0075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2026.116674_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578285","article-title":"Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder","volume":"387","author":"Zhang","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2026.116674_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.intimp.2026.116674_bb0090","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ t cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116674_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a t cell-B cell collaboration","volume":"1283","author":"Meike Mitsdoerffer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116674_bb0100","article-title":"The role of b cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders","volume":"10","author":"Silke H\u00e4usser-Kinzel","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116674_bb0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Joseph J Sabatino","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.intimp.2026.116674_bb0110","article-title":"Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease","volume":"238","author":"Tao-Xiang Chen","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116674_bb0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19+ b-cell counts and infusion intervals as a surrogate for long-term b-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2019","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116674_bb0120","article-title":"Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis","volume":"9","author":"Marina Rode von Essen","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.intimp.2026.116674_bb0125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ t cells in the pathogenesis of multiple sclerosis","volume":"142","author":"von Essen","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.intimp.2026.116674_bb0130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ana.26216","article-title":"Proinflammatory CD20+ t cells are differentially affected by multiple sclerosis therapeutics","volume":"90","author":"Quendt","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2026.116674_bb0135","article-title":"Increased proportion of CD20+ t cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung b-cell lymphoma: a case report","volume":"355","author":"Jong Kwon Lee","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116674_bb0140","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.24998","article-title":"Depletion of functionally active CD20+ t cells by rituximab treatment","volume":"60","author":"Wilk","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2026.116674_bb0145","article-title":"Ocrelizumab impairs the phenotype and function of memory CD8+ t cells: a 1-year longitudinal study in patients with multiple sclerosis","volume":"10","author":"Amandine Mathias","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.intimp.2026.116674_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000940","article-title":"Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS","volume":"8","author":"Fern\u00e1ndez-Velasco","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"51","key":"10.1016\/j.intimp.2026.116674_bb0155","doi-asserted-by":"crossref","first-page":"25800","DOI":"10.1073\/pnas.1915309116","article-title":"Anti-CD20 therapy depletes activated myelin-specific CD8+ t cells in multiple sclerosis","volume":"116","author":"Sabatino Jr","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.intimp.2026.116674_bb0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing b cells","volume":"209","author":"Barr","year":"2012","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116674_bb0165","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.20111504","article-title":"B and t cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, oct2 and OBF-1","volume":"209","author":"Karnowski","year":"2012","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.116674_bb0170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1084\/jem.194.12.1711","article-title":"Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) t cells","volume":"194","author":"Geginat","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116674_bb0175","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00281-022-00926-8","article-title":"T-cell surveillance of the human brain in health and multiple sclerosis","volume":"44","author":"Smolders","year":"2022","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116674_bb0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.blre.2013.07.002","article-title":"Anti-CD20 monoclonal antibodies: beyond b-cells","volume":"27","author":"Avivi","year":"2013","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.intimp.2026.116674_bb0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nri.2015.18","article-title":"Harnessing the plasticity of CD4(+) t cells to treat immune-mediated disease","volume":"16","author":"DuPage","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116674_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102816","article-title":"Autoreactive memory th17 cells are principally derived from T-bet+ROR\u03b3t+ th17\/1 effectors","volume":"129","author":"Fan","year":"2022","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.intimp.2026.116674_bb0195","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awy069","article-title":"T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention","volume":"141","author":"Jamie van Langelaar","year":"2018","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.intimp.2026.116674_bb0200","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to b-cell depleting therapy with rituximab reverts the abnormalities of t-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2026.116674_bb0205","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.30314","article-title":"The anti-CD20 antibody rituximab reduces the th17 cell response","volume":"63","author":"van de Veerdonk","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2026.116674_bb0210","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/acn3.70042","article-title":"Reconstitution of CXCR3+ CCR6+ Th17.1-like t cells in response to ofatumumab therapy in patients with multiple sclerosis","volume":"12","author":"Yang","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116674_bb0215","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/acn3.51965","article-title":"Repeated iv anti-CD20 treatment in multiple sclerosis: long-term effects on peripheral immune cell subsets","volume":"11","author":"Feige","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116674_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2026.116674_bb0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nri2729","article-title":"Effector and regulatory B cells: modulators of CD4+ T cell immunity","volume":"10","author":"Frances","year":"2010","journal-title":"Nat. Rev. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:57:11Z","timestamp":1778821031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926005199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S1567576926005199"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116674","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of anti-CD20 therapy on circulating T cells in patients with neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116674"}}